Status checked · August 2026
BPC-157 Providers — and Why This Page Ranks None
BPC-157 is not on FDA's 503A Bulks List. No compounding pharmacy can lawfully prepare it today, so every seller advertising it is doing something we would not rank. This page stays here, without a table, until that changes.
On this page
Why there's no ranking here
Compounding pharmacies in the United States cannot work from any bulk ingredient they choose. Under section 503A of the Food, Drug, and Cosmetic Act, a substance that is not an approved drug generally has to appear on FDA's 503A Bulks List before a pharmacy may compound with it. BPC-157 is not on that list.
That single fact explains something readers write to us about: one clinic sells BPC-157 without hesitation and another says it cannot. Both are describing the same rule. The second one is following it.
So a board here would not be a ranking of the best BPC-157 providers. It would be a ranking of the sellers least troubled by the rule — and it would put this site's name behind them. We would rather publish an empty page that explains itself.
What actually happened at FDA
FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and took up seven peptides for possible addition to the 503A list, BPC-157 among them. Two details from that meeting matter more than the headlines it produced.
FDA's own staff said no
The agency's presentation proposed that BPC-157 not be included on the list — the same recommendation it made for all seven substances. The committee advises; it does not decide. A recommendation that runs against the agency's own staff position is not a green light.
It was evaluated for something else entirely
FDA assessed BPC-157 as a treatment for ulcerative colitis — not for tendon repair, gut healing or injury recovery, which is what it is actually sold for. The evidence weighed was the evidence for the nominated use, and that is not the use on the vendor pages.
Nothing has changed legally yet. An advisory recommendation is a step in a process that ends with FDA and HHS acting, and neither has. We pulled FDA's own slides and agenda for all seven peptides rather than relying on the summaries currently circulating, most of which are published by people who sell these compounds.
What would have to be true before we rank anyone
These are the conditions, not a wish list. The first one is binary and currently unmet; the other three are the standard every board on this site already applies.
A lawful basis to compound it
BPC-157 has to be on FDA's 503A Bulks List, added by the agency itself. Until then a pharmacy compounding it is not operating in a gray area — it is outside the framework that makes compounded medicine legal at all.
A named pharmacy that will say so
The same standard every other board here uses: the provider names the facility filling the vial and states its regulatory category on its own site. On the boards we do publish, most providers still fail this one.
A price a reader can actually walk away from
A standing month-to-month figure, not a prepay tier dressed as a monthly rate. We rank on the price you can leave, and we have found sites headlining an annual rate often enough to treat it as the default failure.
A prescriber in the loop
A licensed clinician who evaluates you, not a checkout that ships a vial labeled "for research use only" and leaves the prescription question to you. That label is a legal posture, not a quality tier.
What's being sold right now
Most BPC-157 sold online in the United States moves as a "research chemical," labeled not for human use. That label is what makes the sale possible without a prescription; it is a legal position taken by the seller, not a statement about what is in the vial. Nobody has verified the contents on your behalf, there is no prescriber, and there is no pharmacy whose license is on the line.
We are not going to tell you which of those sellers is best, because the question has no good answer. What we can do is document the compound honestly — what the evidence supports, what doses the studies actually used, and what the safety record looks like — so that whatever you decide, you decide it knowing what is established and what is not.
What we do publish on BPC-157
- BPC-157: what the evidence actually shows
- BPC-157 dosage — what studies used, which is not a recommendation
- BPC-157 side effects, and what the regulatory record shows
- BPC-157 before and after — documented vs. anecdotal
- The FDA compounding decision, read from FDA's own slides
- BPC-157 reconstitution calculator — vial-to-syringe arithmetic only
Looking for a compound we do rank? The peptides with a lawful compounding route have real boards, built on named pharmacies and walk-away prices: sermorelin, GHK-Cu, NAD+ and PT-141, plus the GLP-1s. Everything we rank is indexed on the rankings hub.
Nothing on this page is medical advice. BPC-157 has no FDA-approved product and no approved label, and its evidence base is overwhelmingly animal-model research rather than human clinical trials. The compounding status described here was read against FDA's own published meeting materials in August 2026; this page is updated when the agency acts, so check the date above before relying on it. Ask a licensed clinician whether a peptide program of any kind fits your situation.